Cagrilintide Research: Structure & Amylin Receptor Science

Cagrilintide research overview showing amylin analogue structure, receptor research and lipid modificationv
AXOPEPTIDES RESEARCH LIBRARY

Cagrilintide: Amylin Analogue Structure, Receptor Pharmacology & Scientific Research Overview

Cagrilintide is a synthetic lipidated peptide developed from amylin-family peptide research. This scientific overview examines its molecular architecture, structural modifications, interactions with amylin and calcitonin-family receptors, cryo-electron microscopy research and analytical characterisation.

R
Scientific & Laboratory Research Information

This article is intended for scientific and educational information only. It contains no dosing, reconstitution, administration, injection or personal-use instructions.

PEPTIDE FAMILY Amylin analogue
PEPTIDE SCAFFOLD 37 residues
STRUCTURAL FEATURE Lipidated peptide
RECEPTOR RESEARCH AMY₁R / AMY₂R / AMY₃R / CTR
MOLECULAR OVERVIEW

What Is Cagrilintide?

Cagrilintide is a synthetic peptide developed through structure–activity research involving the amylin peptide family.

Scientific literature describes it as a lipidated amylin analogue. Its design combines an amylin-family peptide backbone with specific amino-acid substitutions and chemical modification.

This makes cagrilintide a useful research subject for examining how peptide engineering influences receptor recognition, molecular stability and receptor-complex dynamics.

Scientific focus

Cagrilintide research is particularly useful for studying the relationship between peptide structure and signalling through calcitonin-family receptor systems.

PEPTIDE FAMILY

What Is Amylin?

Amylin is a naturally occurring peptide belonging to the calcitonin-family peptide system.

The native amylin peptide contains 37 amino-acid residues and has characteristic structural features including an intramolecular disulphide bridge near its N-terminus and an amidated C-terminal residue.

Synthetic analogues can preserve parts of this molecular architecture while incorporating deliberate substitutions or chemical modifications.

NATURAL PEPTIDE Amylin
ANALOGUE DESIGN Sequence modification
RESEARCH MOLECULE Cagrilintide
PEPTIDE CHEMISTRY

Cagrilintide Molecular Architecture

Cagrilintide is based on a 37-residue amylin-family peptide scaffold.

Its structure contains several important molecular features that distinguish it from a simple unmodified linear peptide.

01 37-Residue Backbone

The peptide is built on an amylin-family molecular architecture.

02 Disulphide Bridge

Amylin-based peptides contain a covalent bridge between cysteine residues near the N-terminal region.

03 C-Terminal Amidation

The C-terminal end is chemically amidated rather than remaining as a conventional free carboxyl group.

04 Lipid Modification

Cagrilintide contains an attached lipid-related chemical group linked to the peptide.

MOLECULAR ENGINEERING

Why Is Cagrilintide Lipidated?

Lipidation is a peptide-engineering strategy in which a lipid-related chemical group is attached to a peptide molecule.

In structural research, the lipid conjugation represents an additional molecular component that must be considered alongside the amino-acid sequence.

01 Peptide backbone
+
02 Linker chemistry
+
03 Lipid moiety
=
ENGINEERED PEPTIDE Cagrilintide

Simplified molecular-design illustration rather than a synthesis or preparation protocol.

STRUCTURAL CHEMISTRY

The Cys²–Cys⁷ Disulphide Bridge

Amylin-family peptides contain a characteristic disulphide bridge linking cysteine residues at positions 2 and 7.

A disulphide bridge is a covalent linkage formed between the sulfur-containing side chains of two cysteine residues.

RESIDUE Cys²
S — S
RESIDUE Cys⁷

This local structural constraint contributes to the molecular architecture presented to receptor-binding sites.

RECEPTOR PHARMACOLOGY

Which Receptors Are Studied With Cagrilintide?

Recent structural research has examined cagrilintide in complexes with three amylin-receptor phenotypes and the calcitonin receptor.

AMYLIN RECEPTOR AMY₁R
AMYLIN RECEPTOR AMY₂R
AMYLIN RECEPTOR AMY₃R
CALCITONIN RECEPTOR CTR

These receptor systems belong to the broader calcitonin-family signalling network.

RECEPTOR ARCHITECTURE

How Are Amylin Receptors Formed?

Amylin receptors are unusual because they are not defined by a single receptor protein alone.

They are formed when the calcitonin receptor (CTR) associates with one of three receptor activity-modifying proteins (RAMPs).

CTR + RAMP1 AMY₁R
CTR + RAMP2 AMY₂R
CTR + RAMP3 AMY₃R

The presence of different RAMP proteins can change receptor pharmacology and ligand interactions.

CALCITONIN-FAMILY RESEARCH

Cagrilintide & the Calcitonin Receptor

The calcitonin receptor can also be expressed independently of RAMP proteins.

Structural work has investigated cagrilintide bound directly to CTR as well as CTR-containing amylin-receptor complexes.

Important distinction

CTR and the three amylin-receptor phenotypes share a receptor component but are not pharmacologically identical receptor systems.

CRYO-ELECTRON MICROSCOPY

Structural Biology of Cagrilintide-Receptor Complexes

Cryogenic electron microscopy, commonly abbreviated cryo-EM, allows researchers to study large molecular complexes at near-atomic resolution.

In 2025, researchers reported structures of cagrilintide bound to active Gs-coupled AMY₁R, AMY₂R, AMY₃R and CTR complexes.

Peptide Orientation

Structural maps reveal how the peptide occupies the receptor-binding region.

Residue Contacts

Individual amino-acid interactions can be examined within the peptide-receptor complex.

Receptor Conformation

Structural models can reveal different receptor conformational states.

MOLECULAR DYNAMICS

Why Are Receptor Dynamics Important?

Receptor structures are not completely rigid.

Structural research indicates that cagrilintide can produce different conformational dynamics across calcitonin-family receptor complexes.

PEPTIDE Cagrilintide
RECEPTOR AMYR / CTR
STRUCTURAL QUESTION Conformational dynamics

Comparing these dynamics with other amylin-family or calcitonin-family peptides can help researchers investigate structure–activity relationships.

EXPERIMENTAL SCIENCE

How Is Cagrilintide Studied?

01 Chemical Sequence & modification
02 Structural Cryo-EM complexes
03 Cellular Receptor signalling
04 Preclinical Controlled models

Each experimental level answers different questions. A molecular interaction observed in a receptor complex should remain described as a molecular finding rather than being converted into a broader claim.

ANALYTICAL CHEMISTRY

Laboratory Analysis of Cagrilintide

Modified peptides can require complementary analytical methods because sequence, purity and attached chemical groups represent separate aspects of molecular characterisation.

01 Chromatography

HPLC can examine sample composition under defined analytical conditions.

02 Mass Spectrometry

Molecular mass-related data can contribute to identification.

03 Peptide Sequence

Sequence information helps define the peptide backbone being investigated.

04 Modification Analysis

Lipid conjugation and other structural modifications form part of the complete molecular identity.

PubChem Chemical Representation

PubChem currently lists a cagrilintide acetate representation under CID 164618153 with molecular formula C194H312N54O59S2 and molecular weight of approximately 4409 g/mol.

Researchers should check which salt or chemical form is being represented before comparing molecular formulas between databases or analytical records.

ANALYTICAL INTERPRETATION

Purity, Identity & Structural Form

PURITY

Sample composition

Describes chromatographic composition under the stated analytical conditions.

IDENTITY

Which molecule?

Addresses whether analytical evidence corresponds to the expected molecular species.

STRUCTURAL FORM

Which representation?

Modified peptides may exist as different salt or chemically represented forms.

Do not use HPLC purity as a substitute for identity.

A high chromatographic purity result does not by itself establish peptide sequence, molecular mass or chemical modification.

SCIENTIFIC CAUTION

Important Limitations When Reading Cagrilintide Research

  • Cagrilintide is a modified amylin analogue rather than native amylin.
  • AMY₁R, AMY₂R and AMY₃R are distinct receptor phenotypes.
  • CTR and amylin receptors share structural components but should not be treated as identical.
  • Structural binding and functional signalling are different experimental questions.
  • Cryo-EM structures represent experimentally resolved molecular states rather than every possible receptor state.
  • Cellular observations should remain identified as cellular findings.
  • Preclinical findings should remain identified as preclinical.
  • Chromatographic purity does not by itself establish complete molecular identity.
UNITED KINGDOM

Cagrilintide in the UK Research Context

Research-oriented scientific information should remain clearly separated from medicinal presentation and personal-use guidance.

UK regulatory assessment can consider explicit and implicit product claims, pharmacological properties, intended purpose and the way a product is presented through websites, labelling, advertising, social media and other promotional material.

A scientific article should therefore remain consistent with its laboratory and research positioning throughout.

This article intentionally contains no:
Dosing Reconstitution Injection guidance Administration Treatment claims Personal-use guidance Body-composition content Bodybuilding content Biohacking advice Testimonials
AXOPEPTIDES RESEARCH CATALOGUE

Explore Research Peptides

Browse the AxoPeptides laboratory research catalogue and scientific product information.

View Research Catalogue
SCIENTIFIC FAQ

Frequently Asked Research Questions About Cagrilintide

What is cagrilintide?

Cagrilintide is a synthetic lipidated peptide developed from amylin-family analogue research.

Is cagrilintide a peptide?

Yes. It is an engineered peptide based on an amylin-family peptide scaffold.

How long is the cagrilintide peptide scaffold?

Cagrilintide is based on the 37-residue architecture used by amylin-family peptides.

What is a lipidated peptide?

A lipidated peptide contains an attached lipid-related chemical group in addition to its amino-acid backbone.

Does cagrilintide contain a disulphide bridge?

Yes. Amylin-based cagrilintide contains the characteristic Cys²–Cys⁷ disulphide bridge.

Which receptors are investigated with cagrilintide?

Structural studies have examined cagrilintide with AMY₁R, AMY₂R, AMY₃R and the calcitonin receptor.

What are RAMP proteins?

Receptor activity-modifying proteins associate with the calcitonin receptor to generate different amylin-receptor phenotypes.

How is AMY₁R formed?

AMY₁R is formed by association of the calcitonin receptor with RAMP1.

How is AMY₂R formed?

AMY₂R is formed by association of the calcitonin receptor with RAMP2.

How is AMY₃R formed?

AMY₃R is formed by association of the calcitonin receptor with RAMP3.

Has cagrilintide been studied using cryo-EM?

Yes. Cryo-EM structures have been reported for cagrilintide complexes involving all three amylin-receptor phenotypes and CTR.

Does HPLC purity prove cagrilintide identity?

Not by itself. Purity, molecular identity and structural modification are separate analytical questions.

SCIENTIFIC & REGULATORY SOURCES

References & Further Reading

  1. Kruse T, et al. Journal of Medicinal Chemistry. 2021.

    Development of Cagrilintide, a Long-Acting Amylin Analogue.

    View PubMed
  2. Cao J, et al. Nature Communications. 2025.

    Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors.

    View publication
  3. PubChem — Cagrilintide (acetate)

    Chemical identifiers and molecular representation for cagrilintide acetate, CID 164618153.

    View PubChem
  4. MHRA — Borderline Products Guidance

    Current UK guidance concerning claims, intended purpose and presentation when assessing medicinal products.

    View GOV.UK guidance
Scientific & Laboratory Research Information

This page is intended for scientific and educational information. It provides no dosing, reconstitution, administration, injection, treatment or personal-use guidance.